Celltrion’s infliximab biosimilar to be tested for COVID-19
Infliximab has been chosen because of its effective role in treating autoimmune and inflammatory conditions and established safety profile
Read More
Tag: RECOVER
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
